The Turbo-Power laser atherectomy catheter debulks the lesion in a single step and offers remote automatic rotation for precise directional control. Turbo-Power is the only atherectomy device proven and approved for the treat of ISR.
By clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
The rotation of the eccentric fiber pack mitigates dead space between the fibers and is more effective on a greater surface area.⁸
Clinical superiority
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Precise directional control
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
The rotation of the eccentric fiber pack mitigates dead space between the fibers and is more effective on a greater surface area.⁸
Clinical superiority
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Precise directional control
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
1. Dippel et al. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-stent Restenosis: Initial EXCITE ISR Results (2015). JACC 8(1): 92-101.
2. Saxon et al (2013). Heparin bonded, expanded polytetrafluoroethylene lined stent graft in the treatment of femoropopliteal artery disease. JVIR; 24(2).
3. McKinsey J, Zellar T, Rocha-Singh K, et al. Lower Extremity Revascularization Using Directional Atherectomy: 12-Moth Prospective Results of the DEFINITIVE LE Study, JACC Cardiovasc Interv 7 (2014) pp. 923-933.
4. Maehara A, et al. JETSTREAM Atherectomy System can remove superficial calcium in severely calcified peripheral arteries. Abstract Poster, ISET Jan 2013.
5. Babaev A, et al. Tissue Removal Assessment with Ultrasound of the SFA and Popliteal Study (TRUTH): Orbital Atherectomy Acute Date and Intravascular Ultrasound Analysis. JACC Vol 64/11/Suppl B, TCT-131.
6. Maximal luminal gain defined as 50% or greater stenosis reduction.
7. Spectranetics Benchmark Study, unpublished data available upon request. Coll Cardio. 2004;43:1959-1963.
8. Data on file D040242-00
9. Data on file ECO031891
*When comparing 7F Turbo-Power to 2.0 Turbo-Elite. Greater than 10% luminal gain when comparing 6F Turbo- Power to 2.0 Turbo-Elite.
**Excite ISR studied the safety and efficacy of Turbo-Tandem plus PTA and PTA alone. Turbo-Power is substantially equivalent to Turbo-Tandem.
Product availability is subject to country regulatory clearance. Please contact your local sales representative to check the availability in your country.
Always read the label and follow the directions for use.
Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device.
Philips reserves the right to change product specifications without prior notification.
By clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
